Variant screening of PYY 3-36 leads to potent long-acting PYY analogs with superior Y 2 receptor selectivity

• Published in: Science translational medicine Vol. 17; no. 791; p. eadq6392
• Main Authors: Østergaard, Søren, Jessen, Carsten, Paulsson, Johan F, Kasimova, Marina A, Conde-Frieboes, Kilian W, Straarup, Ellen Marie, Skyggebjerg, Rikke Bjerring, Ynddal, Lars, Sanfridson, Annika, Wulff, Birgitte S, Chambers, Adam P
• Format: Journal Article
• Language: English
• Published: United States 26.03.2025
• Subjects: Animals; Blood Glucose - metabolism; Diet, High-Fat; Humans; Male; Mice; Mice, Inbred C57BL; Obesity - drug therapy; Peptide Fragments; Peptide YY - chemistry; Peptide YY - metabolism; Peptide YY - pharmacology; Peptide YY - therapeutic use; Rats; Receptors, Neuropeptide Y - metabolism
• ISSN: 1946-6242
• DOI: 10.1126/scitranslmed.adq6392

Peptide YY (PYY ) has attracted attention in diabetes and obesity research because of its involvement in food intake regulation and glucose homeostasis. Native PYY maintains high potency on the Y receptor with a loss of potency on the Y , Y , and Y receptors. However, PYY has a relatively short half-life, and the selectivity displayed by the native peptide may not be optimal if a long-acting analog is to be developed. We performed variant screening of PYY to identify key canonical amino acids that are pivotal to Y receptor selectivity, potency, and peptide stability. In combination with fatty diacid derivatization, this afforded highly selective long-acting analogs against the Y receptor, which improved glucose metabolism in diabetic / mice. When combined with a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist, these analogs showed superior blood glucose lowering in diabetic ZSF1 rats and greater body weight loss in a high-fat diet-induced mouse model of obesity compared with treatment with the GLP-1 analog alone. One of the tested analogs, PYY1875, has progressed into clinical trials for obesity. Together, our results demonstrate the power of variant screening combined with fatty diacid derivatization in the development of a long-acting, highly efficacious PYY clinical candidate.